PharmaResearch파마리서치
214450 · KOSDAQ · ₩214450 · 파마리서치
₩228,500▼ ₩3,000 (1.30%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩536B | ₩350B | ₩261B | ₩195B | ₩154B |
| Cost of sales | ₩125B | ₩99B | ₩71B | ₩53B | ₩46B |
| Gross profit | ₩411B | ₩251B | ₩190B | ₩142B | ₩108B |
| Operating income | ₩214B | ₩126B | ₩92B | ₩66B | ₩52B |
| Net income | ₩168B | ₩89B | ₩77B | ₩43B | ₩47B |
| Net income to shareholders | ₩165B | ₩92B | ₩77B | ₩41B | ₩47B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩1T | ₩856B | ₩535B | ₩478B | ₩428B |
| Current assets | ₩760B | ₩555B | ₩256B | ₩247B | ₩207B |
| Cash and equivalents | ₩176B | ₩165B | ₩67B | ₩73B | ₩42B |
| Total liabilities | ₩320B | ₩286B | ₩73B | ₩106B | ₩99B |
| Current liabilities | ₩110B | ₩83B | ₩66B | ₩54B | ₩48B |
| Borrowings | ₩8.4B | ₩11B | ₩593M | ₩60B | ₩58B |
| Total equity | ₩724B | ₩569B | ₩462B | ₩372B | ₩328B |
| Shareholders' equity | ₩689B | ₩539B | ₩433B | ₩344B | ₩305B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩183B | ₩138B | ₩65B | ₩59B | ₩65B |
| Capital spending | ₩30B | ₩36B | ₩12B | ₩17B | ₩21B |
| Free cash flow | ₩153B | ₩102B | ₩53B | ₩42B | ₩45B |
| Dividends paid | ₩12B | ₩10B | ₩7.5B | ₩6.3B | ₩5B |
Consolidated where available. Amounts in won.
Also known as: PharmaResearch / 파마리서치 / 214450 / KRX:214450
Source: KRX statistical information